In Vivo Effects of Interleukin 3 in HIV Type 1-Infected Patients with Cytopenia

AIDS Research and Human Retroviruses

Volumn 11, Issue 6, 1995, Pages 731-740

  Scadden, David T ^a   Levine, James D ^a   Bresnahan, Jocelyn ^a   Gere, John ^a   Mcgrath, Jacqueline ^a   Wang, Zhengyu ^a   Resta, Debra J ^b   Young, Diane ^b   Hammer, Scott M ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b Sandoz Pharma Ltd   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT INTERLEUKIN 3;

ADULT; ALLERGIC VASCULITIS; ARTHRALGIA; ARTICLE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DIAPHORESIS; HEADACHE; HEMATOCRIT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALAISE; MALE; NAUSEA; NEUTROPHIL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE COUNT;

ADULT; BLOOD CELL COUNT; COHORT STUDIES; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; INTERLEUKIN-3; LEUKOCYTES, MONONUCLEAR; LEUKOPENIA; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS; RNA, VIRAL; VIRUS CULTIVATION;

EID: 0029056860     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.1995.11.731     Document Type: Article

References (64)

1. Groopman JE, Mitsuyasu RT, DeLeo MJ, Oette DH, and Golde DW: Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. N Engl J Med 1987;317:593-598.
2. Fischi M, Galphin JE, Levine JD, Groopman JE, Henry DH, Kennedy P, Miles S, Robbins W, Starrett B, and Zalusky R: Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med 1990;322:1488-1493.
3. Henry DH, Beall GN, Benson CA, Carey J, Cone LA, Eron LJ, Fiala M, Fischi MA, Gabin SJ, and Gottlieb MS: Recombinant human erythropoietin in the treatment of anemia associated with human inmiunodeficiency virus infection and zidovudine therapy: Overview of four clinical trials. Ann Intern Med 1992; 117: 739-748.
4. Pluda JM, Yarchoan R, and Smith PD: Subcutaneous recombinant granulocyte-macrophage colony-stimulating factor used as a single agent and in an alterating regimen with azidothymidine in leukopenic patients with severe human immunodeficiency virus infection. Blood 1990;76:463-472.
5. Scadden DT, Bering HA, Levine JD, Bresnahan J, Evans L, Epstein C, and Groopman JE: Granulocyte-macrophage colony-stimulation factor mitigates the neutropenia of combined interferon alfa and zidovudine treatment of acquired immune deficiency syndrome-associated Kaposi's sarcoma. J Clin Oncol 1991;9:802-808.
6. Levine JD, Allan JD, Tessitore JH, Falcone N, Galasso F, Israel RJ, and Groopman JE: Recombinant human granulocyte-macrophage colony-stimulating factor ameliorates zidovudine-induced neutropenia in patients with acquired immunodeficiency syndrome (AIDSyAIDS-related complex. Blood 1991;78:3148-3154.
7. Miles SA, Mitsuyasu RT, Moreno J, Baldwin G, Alton NK, Souza L, and Glaspy JA: Combined therapy with recombinant G-CSF and EPO decreases hematologic toxicity from zidovudine. Blood 1991;77:2109-2117.
8. Hardy WD: Combined ganciclovir and recombinant granulocyte-macrophage colony-stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients. J Acquir Immune Defic Syndr 1991;4:S22-S28.
9. Kaplan LD, Kahn JO, Crowe S, Northfelt D, Neville P, Grossberg H, Abrams DI, Tracey J, Mills J, and Volberding PA: Chnical and virologie effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: Results of a randomized trial. J Clin Oncol 1991;9:929-940.
10. Davey RT JR, Davey VJ, Metcalf JA, Zurlo JJ, Kovacs JA, Falloon J, Polis MA, Zunich KM, Masur H. and Lane HC: A phase I/U trial of zidovudine, interferon-a, and granulocyte-macrophage colony-stimulating factor in the treatment of human inmiunodeficiency virus type 1 infection. J Infect Dis 1991;164:43-52.
11. Krown SE, Paredes J, Bundow D, Polsky B, Gold JW, and Flomenberg N: Interferon-a, zidovudine, and granulocyte-macrophage colony-stimulating factor: A phase I AIDS Clinical Trials Group study in patients with Kaposi's sarcoma associated with AIDS. J Clin Oncol 1992;10:1344-1351.
12. Phair JP, Abels RI, McNeill MV, and Sullivan DJ: Recombinant human erythropoietin treatment: Investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome. Arch Intern Med 1993;153:2669-2675.
13. Koyanagi Y, O'Brien WA, Zhao JQ, Gasson JC, and Chen IS: Cytokines alter production of HIV-1 from primaiy mononuclear phagocytes. Science 1988;241:1673-1675.
14. Ihle JN: Biomedical and biological properties of interleukin-3: A lymphokine mediating the differentiation of a lineage of cells which includes prothymocytes and mastlike cells. J Immunol 1983;131: 282.
15. Platzer E, Welte K, Gabrilove JL, et al.: Biological activities of a human pluripotent hemopoietic colony stimulating factor on normal and leukemic cells. J Exp Med 1985;162:1788-1801.
16. Takaue Y, Kawano Y, Reading CL, et al: Effects of recombinant human G-CSF, GM-CSF, IL-3 and IL-la on the growth of purified human peripheral blood progenitors. Blood 1990;76:330-335.
17. Saeland S, Caux C, Favre C, et al.: Effects of recombinant human interleukin-3 on CD34-enriched hematopoietic progenitors and on myeloblastic leukemia cells. Blood 1988;72:1580-1588.
18. Young DA, Lowe LD, and Clark S: Comparison of the Effects of IL-3, granulocyte-macrophage colony-stimulating factor, and macrophage colony-stimulating factor in supporting monocyte differentiation in culture. J Inmiunol 1990;145:607-615.
19. Metcalf D, Begley CG, Johnson GR, et al.: Effects of purified bacterially synthesized murine multi-CSF (IL-3) on hematopoiesis in normal adult mice. Blood 1986;68:46-57.
20. Metcalf D, Begley CG, Nicola N, and Johnson GR: Quantitative responsiveness of murine hemopoietic populations in vitro and in vivo to recombinant multi-CSF (IL-3). Exp Hematol 1987;15:288-295.
21. Stahl CP, Winton EF, Monroe MC, et al: Differential effects of sequential simultaneous, and single agent interleukin-3 and granulocyte-macrophage colony-stimulating factor on megakaryocyte maturation and platelet response in primates. Blood 1992;80: 2479-2485.
22. Mayer P. Valent P, Schmidt G, Liehl E, and Bettelheim P: The in vivo effects of recombinant human interleukin-3: Demonstration of basophil differentiation factor, histamine-producing activity, and priming of GM-CSF-responsiveness progenitors in nonhuman primates. Blood 1989;74:613-621.
23. Ganser A, Lindemann A, Seipelt G, Ottmann OG, Herrmann F, Eder M, Frisch J, Schulz G, Mertelsmann R, and Hoelzer D: Effects of recombinant human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure. Blood 1990;76:666-676.
24. Ganser A, Lindemann A, Seipelt G, et al.: Effects of recombinant human interleukin-3 in aplastic anemia. Blood 1990;76:1.
25. Ganser A, Seipelt G, Lindemann A, Ottmann O, Falk S, Eder M, Herrmann F, Becher R, Hoffken K, Buchner T, Klausmann M, Frisch J, Schulz G, Mertelsmann R, and Hoelzer D: Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes. Blood 1990;76:455-462.
26. Kurzrock R, Talpaz M, Estrov Z, Rosenblum MG, and Gutterman JU: Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. J Clin Oncol 1991;9:1241-1250.
27. Lindemann A, Ganser A, Herrmann J, et al: Biologic effects of recombinant human interleukin-3 in vivo. J Clin Oncol 1991;9:2120-2127.
28. Hoelzer D, Seipelt G, and Ganser A: Interleukin-3 alone and in combination with GM-CSF in the treatment of patients with neoplastic disease. Semin Hematol 1991;28:17-24.
29. Biesma B, Willemse PH, Mulder NH, et al: Effects of interleukin-3 after chemotherapy for advanced ovarian cancer. Blood 1992;80:1141-1148.
30. Brugger W, Bross K, Frisch J, et al: Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide and cisplatin. Blood 1992;79:1193-1200.
31. Postmus PE, Gietema JA, Damsma O, et al: Effects of recombinant human interleukin-3 in patients with relapsed small-cell lung cancer treated with chemotherapy: A dose-finding study. J Clin Oncol 1992;10:1131-1140.
32. Dunbar CE, Smith DA, Kimball J, et al: Treatment of diamond-blackfan anemia with hematopoietic growth factors, granulocyte-macrophage colony stimulating factor and interleukin 3: Sustained remissions following IL-3. Br J Haematol 1991;79:316-321.
33. Nemunaitis J, Appelbaum FR, Singer JW, Lilleby K, Wolff S, Greer JP, Bierman P, Resta D, Campion M, Levitt D, Zeigler Z, Rosenfeld C, Shadduck RK, and Buckner CD: Phase I trial with recombinant human interleukin-3 in patients with lymphoma undergoing autologous bone marrow transplantation. Blood 1993;82: 3273-3278.
34. Scadden DT, Zon LI, and Groopman JE: Pathophysiology and management of HIV-associated hematologic disorders. Blood 1989;74: 1455-1463.
35. Wang M, Friedman H, and Djeu J Y: Enhancement of human monocyte function against Candida albicans by the colony-stimulating factors (CSF): IL-3, granulocyte macrophage-CSF, and macrophage-CSF. J Immunol 1989;143:671-677.
36. Dy M, Jankovic D, Ploemacher R, Theze J, and Schneider E: Concomitant histamine, interleukin 4, and interleukin 6 production by hematopoietic progenitor subsets in response to interleukin 3. Exp Hematol 1991;19:934-940.
37. Valent P, Schmidt G, Besemer J, Mayer P, Zenke G, Liehl E, Hinterberger W, Lechner K, Maurer D, and Bettelheim P: Interleukin-3 is a differentiation factor for human basophils. Blood 1989;73:1763-1769.
38. Rothenberg ME, Owen WF, Silberstein DS, Woods J, Soberman RJ, Austen KF, and Stevens RL: Human eosinophils have prolonged survival, enhanced functional properties, and become hy-podense when exposed to human interleukin 3. J Clin Invest 1988; 81:1986-1992.
39. Brunner T, Heusser CH, and Dahinden CA: Human peripheral blood basophils primed by interleukin 3 (IL-3) produce IL-4 in response to immunoglobulin E receptor stimulation. J Exp Med 1993;177:605-611.
40. Schuitemaker H, Kootstra NA, van Oers MH, van Lambalgen R, Tersmette M, and Miedema F: Induction of monocyte proliferation and HTV expression by IL-3 does not interfere with antiviral activity of zidovudine. Blood 1990;76:1490-1493.
41. Scadden DT, Wang Z, and Groopman JE: Quantitation of plasma human immunodeficiency virus type 1 RNA by competitive polymerase chain reaction. J Infect Dis 1992;165:1119-1123.
42. Rayfield M, DeCock K, Heyward W, et al: Mixed human immunodeficiency virus (HIV) infection in an individual: Demonstration of both HIV type 1 and type 2 proviral sequences by using polymerase chain reaction. J Infect Dis 1988;158:1170-1176.
43. Ou CY, Kwok S, and Mitchell SW: DNA amplification for direct detection of HIV-1 DNA of peripheral blood mononuclear cells. Science 1988;239:295-297.
44. Ho DD, Moudgil T, and Alam M: Quantitation of human immunodeficiency virus type-1 in the blood of an infected persons. N Engl J Med 1989;321:1621-1625.
45. Gupta PA, Enrico A, Armstrong J, Doerr M, Ho M, and Rinaldo C: A semiquantitative microassay for measurement of relative of number on blood mononuclear cells infected with human immunodeficiency virus. AIDS Res Hum Retroviruses 1990;6:1193-1196.
46. Dimitrov DH, Melnick JL, and Hollinger FB: Microculture assay for isolation of human immunodeflciency virus type 1 and for titration of infected peripheral blood mononuclear cells. J Clin Microbiol 1990;28:734-737.
47. Hollinger FB (ed.): Quantitative PBMC microculture assay. In: ACTG Virology Manual for HIV Laboratories. Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, 1993, pp. MIC1-MIC5.
48. Coombs RW, Collier AC, Allain JP, Nikora B, Leuther M, Gjerset GF, and Corey L: Plasma viremia in human inmiunodeficiency vmis infection. N Engl J Med 1989;321:1626-1631.
49. Holodniy M, Kim S, Katzenstein D, Konrad M, Groves E, and Merigan TC: Inhibition of human immunodeficiency virus gene amplification by heparin. J Clin Micriobiol 1991;29:676-679.
50. Saag MS, Crain MJ, Decker WD, Campbell-Hill S, Robinson S, Brown WE, Leuther M, Whitley RJ, Hahn BH, and Shaw GM: High-level viremia in adults and children infected with human immu-nodeficiency virus: Relation to disease stage and CD4+ lymphocyte levels. J Infect Dis 1991;164:72-80.
51. Hollinger FB (ed.): Quantitative plasma culture assay. In: ACTG Virology Manual for HIV Laboratories. Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, 1993, pp. PLA1-PLA4.
52. Scadden DT, Wang A, Zsebo KM, and Groopman JE: In vitro effects of stem cell factor or interleukin-3 on myelosuppression associated with AIDS. AIDS 1994;8:193-196.
53. Pemo CF, Yarchoan R, Cooney DA, Hartman NR, Webb DS, Hao Z, Mitsuya H, Johns DG, and Broder S: Replication of human immunodeficiency virus in monocytes. J Exp Med 1989; 169:933-951.
54. Poli G, Bressler P, Kinter A, Duh E, Timmer WC, Rabson A, Justement JS, Stanley S, and Fauci AS: Interleukin-6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor alpha by transcriptional and posttranscriptional mechanisms. J Exp Med 1990;172:151-158.
55. Folks TM, Clouse KA, Justement J, Rabson A, Duh E, Kehrl JH, and Fauci AS: Tumor necrosis factor-a induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci USA 1989;86:2365-2368.
56. Coopman SA, Johnson RA, Platt RF, and Stem RA: Cutaneous disease and drug reactions in HTV infection. N Engl J Med 1993;328:1670-1674.
57. Geissler K, Valent P, Mayer P, et al.: Recombinant human interleukin-3 expands the pool of circulating hematopoietic progenitor cells in primates-synergism with recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1990;75:2305-2310.
58. Donahue RE, Seehra J, Metzger M, et al.: Human IL-3 and GM-CSF act synergistically in stimulating hematopoiesis in primates. Science 1988;241:1820-1823.
59. Leary AG, Ikebuchi K, Hirai Y, et at.: Synergism between interleukin-6 and interleukin-3 supporting proliferation of human hematopoietic stem cells: Cotnparison with interleukin-la. Blood 1988;71:1759-1763.
60. Bartelmez SH, Bradley TR, Bertoncello I, et al: Interleukin-1 plus interleukin-3 plus colony-stimulating factor 1 are essential for clonal proliferation of primitive myeloid bone marrow cells. Exp Hematol 1989;17:240-245.
61. Geissler K, Valent P, Bettelheim P, et al.: In vivo synergism of recombinant human interleukin-3 and recombinant human interleukin-6 on thrombopoiesis in primates. Blood 1992;79:1155-1160.
62. Ikebuchi K, Wong G, Clark S, et al: Interleukin-6 enhancement of interleukin-3 dependent proliferation of multipotential hemopoietic progenitors. Proc Natl Acad Sci USA 1987;84:9035-9036.
63. Ganser A, Lindemann A, Ottmann O, et al.: Sequential in vivo treatment with two recombinant human hematopoietic growth factors (interleukin-3 and granulocyte-macrophage colony-stimulating factor) as a new therapeutic modality to stimulate hematopoiesis: Results of a phase I study. Blood 1992;79:2583-2591.
64. Kawano Y, Takaue Y, Hirao A, Abe T, Saito SI, Matsunaga K, Watanabe T, Hirose M, Ninomiya T, Kuroda Y, Yokobayashi A, and Asano S: Synergistic effect of recombinant interferon-7 and interleukin-3 on the growth of immature human hematopoietic progenitors. Blood 1991;77:2118-2121.